Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ONL
4401
Orion Office REIT
ONL
$137M
| $142K | ﹤0.01% |
62,635
+62,632
| +2,087,733% | +$148K |
2022 Q1
15 quarters
|
|
4402
Kaspi.kz JSC
KSPI
$17.9B
| $141K | ﹤0.01% |
1,810
+1,010
| +126% | +$76.3K |
2025 Q3
1 quarter
|
|
4403
FT Vest US Equity Deep Buffer ETF November
DNOV
$405M
| $141K | ﹤0.01% |
2,891
-1,152
| -28% | -$55.1K |
2024 Q3
5 quarters
|
|
4404
Innovator US Equity Power Buffer ETF June
PJUN
$884M
| $141K | ﹤0.01% |
3,360
-1,529
| -31% | -$63.3K |
2025 Q3
1 quarter
|
|
4405
Outset Medical
OM
$74.4M
| $140K | ﹤0.01% |
37,682
+3,356
| +10% | +$28.8K |
2022 Q1
15 quarters
|
|
|
QMMM
4406
DELISTED
QMMM Holdings
QMMM
| $139K | ﹤0.01% |
1,163
| – | – |
2024 Q3
5 quarters
|
|
4407
Bausch Health
BHC
$2.17B
| $139K | ﹤0.01% |
19,965
+12,875
| +182% | +$84.7K |
2013 Q2
50 quarters
|
|
4408
FT Vest US Equity Enhance & Moderate Buffer ETF November
XNOV
$57.8M
| $138K | ﹤0.01% |
3,649
-1,768
| -33% | -$65.8K |
2024 Q3
5 quarters
|
|
|
ATYR
4409
aTyr Pharma
ATYR
$28.2M
| $136K | ﹤0.01% |
174,182
-167,177
| -49% | -$137K |
2024 Q4
4 quarters
|
|
|
WLTH
4410
Wealthfront Corp
WLTH
$1.57B
| $136K | ﹤0.01% |
+10,036
| New | +$133K |
2025 Q4
0 quarters
|
|
|
SNCR
4411
DELISTED
Synchronoss Technologies
SNCR
| $136K | ﹤0.01% |
15,889
-167
| -1% | -$1.03K |
2018 Q4
28 quarters
|
|
4412
CSP Inc
CSPI
$76.3M
| $135K | ﹤0.01% |
10,838
+971
| +10% | +$11.9K |
2024 Q3
5 quarters
|
|
4413
CPI Card Group
PMTS
$288M
| $135K | ﹤0.01% |
9,210
+757
| +9% | +$11.4K |
2023 Q1
11 quarters
|
|
4414
HF Foods Group
HFFG
$90.6M
| $135K | ﹤0.01% |
62,706
+6,132
| +11% | +$14.8K |
2019 Q2
26 quarters
|
|
4415
Innovator Premium Income 15 Buffer ETF April
LAPR
$11.3M
| $133K | ﹤0.01% |
5,310
-554
| -9% | -$14K |
2025 Q2
2 quarters
|
|
|
LMRI
4416
Lumexa Imaging Holdings
LMRI
$991M
| $133K | ﹤0.01% |
+7,200
| New | +$130K |
2025 Q4
0 quarters
|
|
4417
Invesco Leisure and Entertainment ETF
PEJ
$363M
| $132K | ﹤0.01% |
2,160
| – | – |
2023 Q2
10 quarters
|
|
4418
FT Vest US Equity Deep Buffer ETF June
DJUN
$359M
| $132K | ﹤0.01% |
2,796
-1,389
| -33% | -$65K |
2024 Q3
5 quarters
|
|
4419
FT Vest US Equity Enhance & Moderate Buffer ETF September
XSEP
$138M
| $132K | ﹤0.01% |
3,119
+1,456
| +88% | +$61K |
2024 Q3
5 quarters
|
|
4420
Eledon Pharmaceuticals
ELDN
$202M
| $132K | ﹤0.01% |
87,472
+7,719
| +10% | +$18.3K |
2024 Q4
4 quarters
|
|
4421
Listed Funds Trust Roundhill Magnificent Seven ETF
MAGS
$5.42B
| $132K | ﹤0.01% |
2,000
-1,160
| -37% | -$76.6K |
2025 Q3
1 quarter
|
|
|
HUYA
4422
Huya Inc
HUYA
$525M
| $132K | ﹤0.01% |
+45,774
| New | +$134K |
2025 Q4
0 quarters
|
|
4423
Tenaya Therapeutics
TNYA
$126M
| $132K | ﹤0.01% |
185,001
+185,000
| +18,500,000% | +$252K |
2022 Q1
15 quarters
|
|
|
CARL
4424
Carlsmed
CARL
$390M
| $131K | ﹤0.01% |
10,633
+1,021
| +11% | +$13.6K |
2025 Q3
1 quarter
|
|
|
ZJUL
4425
Innovator Equity Defined Protection ETF - 1 Yr July
ZJUL
$195M
| $131K | ﹤0.01% |
4,516
+3,152
| +231% | +$91K |
2025 Q3
1 quarter
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.